Report of a virtual meeting 21–23 June 2022
Relapsing malaria caused by Plasmodium vivax parasites poses a significant challenge to global malaria elimination efforts. About one third of the population remains at risk of contracting P. vivax malaria, and 85% of P. vivax infections stem from reactivated latent parasites, leading to chronic ana...emia and increased morbidity and mortality. In addition to diagnostic tools that can detect the acute, blood-stage of P. vivax, new tools are needed to detect the dormant infections before they reactivate and contribute to morbidity and onwards transmission
more
WHO recommends artemisinin-based combination therapies for treating uncomplicated malaria, alongside studies to monitor treatment effectiveness. Given the threat of antimalarial resistance, including partial resistance in several African countries, molecular tools are vital for tracking resistance. ...In 2015, WHO launched the External Quality Assessment scheme for nucleic acid amplification testing to ensure reliable lab results. Coordinated by WHO and operated by the United Kingdom National External Quality Assessment Service for Parasitology, the scheme provides quality-controlled specimens and reports to help improve testing accuracy. Experts recently discussed expanding the scheme to include antimalarial resistance markers.
more
Meeting report, Kampala, Uganda,
7–8 November 2023
The purpose of this guide is to provide updated clinical guidance on TB/HIV, with an emphasis on diagnostic aspects—including new techniques—as well as current treatment, while maintaining a public health approach. By compiling and consolidating the latest World Health Organization recommendatio...ns on the subject into a single guide, the aim is to create a reference and consultation document that is frequently used, and that unifies and standardizes the comprehensive management of TB/HIV co-infection in healthcare facilities based on the principle of “two diseases, one patient.” It also seeks to support the updating of national standards and guidelines on co-infection and to complement the coordinated work that must exist between TB and HIV prevention and control programs at all levels, within the framework of the twelve internationally recommended TB/HIV collaborative activities.
more
Le document intitulé « Guide du conseiller – Renforcement des capacités de lutte contre le paludisme » est un guide pratique destiné aux conseillers techniques travaillant au sein des Programmes nationaux de lutte contre le paludisme (PNLP), principalement dans des pays partenaires souten...us par l’USAID. Il a pour objectif de fournir des orientations concrètes sur la manière d’appuyer efficacement les PNLP dans la gestion, la planification stratégique, la mise en œuvre des subventions du Fonds mondial et le renforcement des capacités organisationnelles et humaines. Le guide décrit le rôle des conseillers, les étapes de leur intégration, les outils d’évaluation de performance, ainsi que les bonnes pratiques pour collaborer avec les partenaires locaux. Il met l’accent sur une approche participative, le transfert de compétences et la durabilité des interventions, dans une perspective d’amélioration continue des systèmes de santé.
more
Pillar 3 of the Global technical strategy for malaria 2016–2030 calls for the transformation of malaria surveillance into a core intervention in all malaria-endemic countries, as well as in countries which have eliminated malaria but remain susceptible to re-establishment of transmission. This ref...erence manual covers subjects that are relevant to both settings.
The target readership of this manual includes staff working in ministries of health, national malaria programmes and health information systems; partners involved in malaria surveillance; and WHO technical officers who advise countries on malaria surveillance.
more
Le pilier 3 de la Stratégie technique mondiale de lutte contre le paludisme 2016–2030 consiste à faire de la surveillance du paludisme une intervention de base dans tous les pays d’endémie palustre et dans ceux ayant éliminé le paludisme mais où la transmission pourrait reprendre. Ce nouve...au manuel traite de thématiques qui se rapportent tant aux contextes dans lesquels on cherche à diminuer la charge du paludisme qu’à ceux où le paludisme est en cours d’élimination.
more
Implementation reference guide. This Malaria Surveillance Assessment Toolkit implementation reference guide is a comprehensive reference document, as well as a step by-step guide. It aligns and adapts available tools into a single set of standardized tools, which can be used to conduct malaria surve...illance assessments across all transmission settings. Use of these standardized tools allows comparison of results between countries and within the same country over time, enabling countries to track their progress towards surveillance system strengthening.
more
Anopheles stephensi is an invasive mosquito species which has been found spreading across Africa. While this species presents a new challenge for malaria control on the continent, its surveillance and management have been ongoing in Asia for many years. This document aims to summarize key lessons fr...om 3 countries – India, the Islamic Republic of Iran and Sri Lanka – that have been working to control An. stephensi. It is hoped that their experiences and insights will be valuable for countries encountering An. stephensi for the first time.
more
This practical document is available to support programmes and partners to design and implement risk communication strategies to achieve high uptake of malaria vaccination.
This practical document is available to support programmes and partners to design and implement risk communication strategies to achieve high uptake of malaria vaccination.
Clinical Pharmacology: Advances and Applications, 2025:17 29–47
Preferred product characteristics and clinical development considerations
Tropical Medicine and Health (2023) 51:29
Two malaria vaccines are currently WHO prequalified and recommended1 for use to prevent
P. falciparum malaria in young children, the RTS,S/AS01 vaccine, currently manufactured by
GlaxoSmithKline (GSK), and the R21/Matrix-M vaccine, manufactured by Serum Institute of India
Pvt (SII)
The aim of this protocol is to support the conduct of entomological comparative efficacy assessments for vector control products and the associated non-inferiority analysis. This evidence is used to inform discussions within the guidelines development context as to whether a new vector control prod...uct should be considered as covered by one or more existing WHO recommendations or not. Alternatively, the evidence may inform the extension of an existing WHO recommendation or the development of a new one, provided that non-inferiority is demonstrated
more
Malaria Journal (2021) 20:190